Skip to Content
Merck
All Photos(2)

Documents

A0980

Sigma-Aldrich

AM281

≥98% (HPLC)

Synonym(s):

1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide, AM 281

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C21H19Cl2IN4O2
CAS Number:
Molecular Weight:
557.21
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white

solubility

DMSO: >6 mg/mL
H2O: insoluble

storage temp.

2-8°C

SMILES string

Cc1c(nn(-c2ccc(Cl)cc2Cl)c1-c3ccc(I)cc3)C(=O)NN4CCOCC4

InChI

1S/C21H19Cl2IN4O2/c1-13-19(21(29)26-27-8-10-30-11-9-27)25-28(18-7-4-15(22)12-17(18)23)20(13)14-2-5-16(24)6-3-14/h2-7,12H,8-11H2,1H3,(H,26,29)

InChI key

AJFFBPZYXRNAIC-UHFFFAOYSA-N

Gene Information

rat ... Cnr1(25248)

Application

AM281 has been used as a cannabinoid 1 receptor antagonist:
  • to study its effects on memory deficit following naloxone-precipitated morphine withdrawal in mice
  • to study the role of CB1 receptor system in modulating acetaldehyde-induced effects in rats during the extinction-, relapse-, and conflict-experiments
  • to study its effect on scopolamine-induced memory deficit using object recognition paradigm
  • to block synthetic cannabinoid (HU210)-induced analgesia in the ventrolateral orbital cortex (VLO) to evaluate the effect of CB1 receptors on the VLO modulation of pain

Biochem/physiol Actions

AM281 is less lipophilic compared to its analog SR 141716A, a cannabinoid receptor antagonist. AM281 may prevent memory deficit post morphine withdrawal by inhibiting cannabinoid receptors in mice.
Potent and selective CB1 cannabinoid receptor antagonist/inverse agonist

Features and Benefits

This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Golnaz Vaseghi et al.
Basic & clinical pharmacology & toxicology, 111(3), 161-165 (2012-03-21)
Morphine withdrawal leads to the activation of endocannabinoid system and cognitive deficits. The aim of this study was to evaluate the effects of AM281, a cannabinoid antagonist/inverse agonist, on memory deficit following naloxone-precipitated morphine withdrawal in mice. Male mice were
Yuwei Wu et al.
Neuroscience letters, 736, 135286-135286 (2020-08-04)
The prefrontal ventrolateral orbital cortex (VLO) is involved in antinociception. It has been found that dopamine receptors, adrenoceptors, serotonin receptors and μ-opioid receptors are involved in this effect through direct/indirect activation of the VLO output neurons. However, the effect of
Francisco Molina-Holgado et al.
Molecular and cellular neurosciences, 28(1), 189-194 (2004-12-21)
Cannabinoids (CBs) are neuroprotective in vivo and in vitro, but the mechanisms of their actions are unknown. The aim of this study was to elucidate the signaling pathways that mediate the protective effect of CBs on primary cultured neurons. The
A N Gifford et al.
Neuroscience letters, 238(1-2), 84-86 (1998-02-17)
The SPECT ligand AM 281, a less lipophilic analog of the cannabinoid receptor antagonist SR 141716A, robustly potentiated electrically-evoked release of acetylcholine from superfused hippocampal slices and prevented the inhibition of acetylcholine release by the cannabimimetic drug WIN 55212-2. These
Edgar Alfonso Romero-Sandoval et al.
Molecular pain, 5, 25-25 (2009-05-30)
Cannabinoid receptor type 2 (CBR2) inhibits microglial reactivity through a molecular mechanism yet to be elucidated. We hypothesized that CBR2 activation induces an anti-inflammatory phenotype in microglia by inhibiting extracellular signal-regulated kinase (ERK) pathway, via mitogen-activated protein kinase-phosphatase (MKP) induction.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service